Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inclusion body myositis (IBM).

N Gayathri1, Anisya-Vasanth, M Veerendra Kumar

  • 1Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.

Clinical Neuropathology
|April 25, 2000
PubMed
Summary

Inclusion body myositis, a progressive muscle weakness disorder, presents distinct pathological features. Sporadic and hereditary forms show unique inclusion body characteristics, with no response to immunosuppressive treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights from Magnetic Evoked Field Analysis in Patients with Wilson's Disease.

Neurology India·2022
Same author

A detailed review on advanced oxidation process in treatment of wastewater: Mechanism, challenges and future outlook.

Chemosphere·2022
Same author

Silver Jubilee Year of Annals of Indian Academy of Neurology: Commemorative Volume.

Annals of Indian Academy of Neurology·2022
Same author

Hereditary neuropathies: Genetics and utility of nerve biopsy.

Indian journal of pathology & microbiology·2022
Same author

Association of Infantile Spasms and Hypsarrhythmia with Primary Microcephaly- Three Case Reports.

Annals of Indian Academy of Neurology·2021
Same author

Exposure to the neurotoxin 3-nitropropionic acid in neuronal cells induces unique histone acetylation pattern: Implications for neurodegeneration.

Neurochemistry international·2020

Area of Science:

  • Neurology
  • Pathology
  • Genetics

Background:

  • Inclusion body myositis (IBM) is a progressive neuromuscular disorder characterized by muscle weakness.
  • Distinguishing between sporadic (s-IBM) and hereditary (h-IBM) forms is crucial for understanding disease mechanisms.
  • Clinical presentation can be misleading, often delaying accurate diagnosis.

Purpose of the Study:

  • To describe the clinical, histological, immunohistochemical, and ultrastructural features of five IBM cases.
  • To compare the pathological characteristics of sporadic and hereditary forms of IBM.
  • To evaluate treatment responses in IBM patients.

Main Methods:

  • Case study analysis of five patients (3 men, 2 women) with IBM.
  • Clinical evaluation including muscle strength assessment and creatine phosphokinase (CPK) levels.

Related Experiment Videos

  • Electromyography (EMG) to assess muscle and nerve function.
  • Histopathological examination including routine staining, Congo red staining, and immunohistochemistry for ubiquitin, beta-amyloid, SMI-31, and hyperphosphorylated-tau.
  • Ultrastructural analysis to identify subcellular abnormalities.

    • Main Results:

    • All patients exhibited chronic progressive weakness in all four extremities, sparing cranial muscles.
    • EMG showed myopathic features in four patients and neurogenic changes in two.
    • Histopathology confirmed IBM with characteristic eosinophilic inclusions.
    • Sporadic IBM inclusions were congophilic and positive for ubiquitin, beta-amyloid, and SMI-31.
    • Hereditary IBM inclusions lacked congophilia; hyperphosphorylated-tau was negative in both forms.
    • Ultrastructural analysis revealed membranous whorls.

    Conclusions:

    • IBM presents with characteristic pathological hallmarks, including unique inclusion bodies in sporadic and hereditary forms.
    • The findings highlight the distinct molecular signatures of inclusions in s-IBM and h-IBM.
    • Current immunosuppressive therapies, including steroids, are ineffective for treating IBM.